Watch for CLE data in H2 2026 and initial registrational trial readouts for GD and MG in 2027. Strong D2T RA response rates increase probability of success in other indications. Positive sentiment likely to sustain.
Price Chart
Executive Summary
Immunovant reported Q4 FY2026 net loss of $0.73/share, wider than prior year's $0.64 loss, driven by increased R&D spending and $39M batoclimab discontinuation costs. The highlight is strong IMVT-1402 data in D2T RA (72.7% ACR20 at week 16) and cash runway of $902M into potential GD launch, overshadowing the financial results.
Key Financial Metrics
Key Facts
- Q4 net loss $147.9M ($0.73/share) vs $106.4M ($0.64) YoY
- Cash and equivalents $902.1M, providing runway to potential IMVT-1402 launch in GD
- IMVT-1402 D2T RA trial: 72.7% ACR20, 54.5% ACR50, 35.8% ACR70 at week 16 (open label)
- Upcoming catalysts: CLE proof-of-concept data H2 2026; potentially registrational trials in GD, MG, CIDP, SjD with topline data in 2027
- Batoclimab discontinued after Phase 3 TED failures; learnings applied to IMVT-1402
Financial Impact
No direct revenue impact; clinical data de-risks IMVT-1402 pipeline, supporting $5.4B market cap. Cash runway sufficient for multiple registrational trials.
Risk Factors
- Batoclimab discontinuation underscores anti-FcRn class risk in TED
- Open-label results may not replicate in blinded, randomized stages
- Future equity dilution likely given $900M cash burn rate ($505M FY net loss)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3298332 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 11w ago | 8-K | $39.74 $39.12 | ▲ +1.56% | ▲ +2.16% | $27.68 (+30.35%) |
Jul 24, 2026 13w ago | Insider Cluster | $40.09 $43.32 | ▲ +8.06% | ▲ +4.76% | $27.68 (−30.96%) |
Jun 26, 2026 17w ago | Insider Cluster | $38.51 $39.41 | ▲ +2.34% | ▲ +2.62% | $27.68 (−28.12%) |
Jun 26, 2026 17w ago | Insider Cluster | $38.51 $39.41 | ▲ +2.34% | ▲ +2.62% | $27.68 (−28.12%) |
Jun 26, 2026 17w ago | 144 | $38.51 $39.41 | ▲ +2.34% | ▲ +2.62% | $27.68 (−28.12%) |
Jun 26, 2026 17w ago | 144 | $38.51 $39.41 | ▲ +2.34% | ▲ +2.62% | $27.68 (−28.12%) |
Jun 15, 2026 18w ago | 144 | $33.61 $38.77 | ▲ +15.35% | ▲ +15.15% | $27.68 (−17.64%) |
May 28, 2026 21w ago | 144 | $33.30 $38.51 | ▲ +15.65% | ▲ +17.44% | $27.68 (−16.88%) |
May 20, 2026 22w ago | 8-K | $35.56 $35.34 | ▼ −0.62% | ▼ −1.36% | $27.68 (−22.16%) |
May 20, 2026 22w ago | Press Release | $35.56 $35.34 | ▼ −0.62% | ▼ −1.36% | $27.68 (−22.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers